N@N

Keay Nakae Maintained (ALNY) at Strong Buy with Decreased Target to $225 on, Feb 16th, 2024

Keay Nakae of Chardan Capital, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy with Decreased Target from $250 to $225 on, Feb 16th, 2024.

Keay has made no other calls on ALNY in the last 4 months.

There are 7 other peers that have a rating on ALNY. Out of the 7 peers that are also analyzing ALNY, 4 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Andy Chen of "Wolfe Research" Initiated at Hold on, Thursday, February 15th, 2024
• Olivia Brayer of "Cantor Fitzgerald" Reiterated at Hold and Held Target at $165 on, Thursday, February 15th, 2024
• Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $176 on, Tuesday, February 13th, 2024
• Jessica Fung of "JP Morgan" Maintained at Hold with Increased Target to $170 on, Thursday, February 1st, 2024

These are the ratings of the 3 analyists that currently disagree with Keay

---

• Joseph Stringer of "Needham" Reiterated at Strong Buy and Held Target at $200 on, Thursday, February 15th, 2024
• Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $395 on, Friday, December 15th, 2023
• Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $217 on, Thursday, December 14th, 2023

Contributing Sources

---